In contrast, a model based on features used in the MINDACT trial (e.g., HR/HER2 status, histologic grade, tumor size, and nodal status), produced a lower AUC/C-index of 0.60 (95% CI: 0.56–0.64). The gene discussed is ERBB2; the disease is neoplasm.